Intra-Cellular Therapies, Inc.

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
65.71 ^USD	-0.92%		-7.72%	-8.25%

07/05	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	MT
07/05	Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024

Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 02, 2023 at 05:00 pm IST

Intra-Cellular Therapies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 126.17 million compared to USD 71.87 million a year ago. Net loss was USD 24.26 million compared to USD 53.51 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.57 a year ago.
For the nine months, revenue was USD 332.27 million compared to USD 162.45 million a year ago. Net loss was USD 111.1 million compared to USD 212.23 million a year ago. Basic loss per share from continuing operations was USD 1.16 compared to USD 2.26 a year ago.

Latest news about Intra-Cellular Therapies, Inc.

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	07/05	MT
Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises	07/05	MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M	07/05	MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M	07/05	MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024	07/05	CI
Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	23/04	MT
Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	22/04	MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating	22/04	MT
Intra-Cellular Therapies Prices $500 Million Stock Offering	18/04	MT
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating	17/04	MT
BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating	17/04	MT
Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating	17/04	MT
TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating	17/04	MT
Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept	17/04	MT
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade	17/04	MT
Sector Update: Health Care Stocks Higher Late Afternoon	17/04	MT
Top Midday Gainers	16/04	MT
US Stocks Lacking Direction Prior to Powell Remarks, Investors Looking for Signs of Future Rate Cuts by Federal Reserve	16/04	MT
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results	16/04	MT
Transcript : Intra-Cellular Therapies, Inc. - Special Call	16/04
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	16/04	CI
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President	19/03	MT
Intra-Cellular Therapies, Inc. Announces Executive Changes	19/03	CI

Chart Intra-Cellular Therapies, Inc.

Duration

Period

More charts

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Companyâs product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Sector

Pharmaceuticals

Calendar

07:30pm - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Intra-Cellular Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.32 USD

Average target price

90.6 USD

Spread / Average Target

+36.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INTRA-CELLULAR THERAPIES, INC.	-8.25%	7B
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.32%	32.81B
UCB	+52.41%	25B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.98B
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B

Biopharmaceuticals